3 Rx are FDA approved for hidradenitis supprativa (secukinumab, adalimumab, bimekizumab). New JAK1i Povorcitinib in STOP-HS1 and STOP-HS2 ph 3 PCTs (608/619 pts). Povo showed HiSCR50 ~42% vs PBO 29% @wk12. AE: acne, pharyngitis https://t.co/n3FJUOjNuo https://t.co/9YAmPqW44z

🔥A post hoc analysis of SELECT-SWITCH from EULAR 2026: A JAKi vs second TNFi in patients with RA stratified by primary or secondary nonresponse or intolerance to a first TNFi. See the poster: https://t.co/1oBa1fEtaI Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/bTWsJ4jglE

Interferon-α as an Immunologic Driver of Sjögren's Disease Using data from a Sjogren's registry, researchers have shown that IFNα drives Sjögren's disease, and can be elevated a decade before diagnosis. This study assessed the role of type 1 interferon (IFNα) in its onset and https://t.co/0BDDvR5cUB

Persistence of education and monitoring is crucial to optimal gout management Optimal gout care is dependent on having a well-informed health care provider who recognizes and follows the ACR gout management recommendations. It is important that the misconceptions and myths held https://t.co/wDvgwUg2P1

Pragmatism in Gout: How therapeutic choices can have multiple benefits Drugs prescribed to calm flares or lower uric acid are designed with one primary goal in mind, yet many also produce meaningful effects beyond the joints. Some of those secondary effects are unwelcome; such https://t.co/QvXAwFM7LJ

Future therapies (in development) for gout - the goal is durable crystal depletion. Created by: Dr. Aravind Palraj @rheumat_aravind for RheumNow. https://t.co/rzP8usVZnT https://t.co/ZDuVWqT2TA

Psoriasis = Myocardial Dysfunction (unrelated to Cardiometabolic Risk Factors) 1010 PsO pts vs controls w/o skin dz, assessed clinically & by ECHO. PSO pts (even w/ controlled dz) had signif more myocardial dysfunction (17% vs 6%). Higher BMI & DM independently assoc w/ https://t.co/MjcRmgyCWX

STOP-HZ trial - 30 #RA pts going on tofacitinib given Shingrix (RZV) on day 1 & wk 8 & started Tofa on d1 or wk8. @wk 12 VZV responses incr in both (2.66 & 2.91 fold incr). @wk 4, d1 Tofa had fewer ≥1.5-fold VZV vs wk8 (44.8% vs 80%); BUT can you wait 8wks to start JAKi? https://t.co/tH0zPgBbHQ

Calcium Pyrophosphate Deposition Dz new terminology from 2026 G-CAN consensus. Preferred: - acute CPP crystal arthritis - Chronic CPP crystal arthritis - Chronic CPP crystal arthritis - OA w/ CPP - Chondrocalcinosis (xray) * Pseudogout is obsolete https://t.co/L95N2ObHr3 https://t.co/ST7RkJa8BR

An AI model trained from routine electronic health record data of 3.7 million individuals predicted cancer 1 year before clinical onset, no less promoted accuracy in detection, staging, treatment response, and prognosis https://t.co/ORrpJ2vIcR https://t.co/ymJWRAYOSw

UTSW observational study of labs (n 14,199) changes w/ MTX use in 2,439 pts (13% RA, 11% PsO/PsA, 15% inflam arthritis) - found no difference in labs q3 vs q6 mos. No signif correlation betw monitoring intervals & changes in ALT, AST,WBC, HCT, MCV, PLT, FIB-4. Small https://t.co/gKwA7juexG